Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis & Investment Frameworks
Ionis Pharmaceuticals, Inc. (IONS) stock analysis on Invetso. Review Ionis Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Ionis Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Ionis Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $7.36B
- Revenue: $944.00M
- ROE: -110.84%
- ROIC: -20.37%
- Dividend Yield: N/A
About Ionis Pharmaceuticals, Inc.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Ionis Pharmaceuticals, Inc. (IONS) across the following frameworks:
- Ionis Pharmaceuticals, Inc. 10Y Growth Potential
- Ionis Pharmaceuticals, Inc. Scenario Analysis
- Ionis Pharmaceuticals, Inc. Risks & Opportunities
- Ionis Pharmaceuticals, Inc. Economic Moat
- Ionis Pharmaceuticals, Inc. Business Model
- Ionis Pharmaceuticals, Inc. Management
- Ionis Pharmaceuticals, Inc. SWOT Analysis
- Ionis Pharmaceuticals, Inc. Porter's 5 Forces
- Ionis Pharmaceuticals, Inc. PESTLE Analysis
- Ionis Pharmaceuticals, Inc. ESG Analysis